Study Finds 1 in 3 U.S. Adults Miss 2026 LDL Goals, Rising to 4 in 5 Heart Patients
Updated
Updated · Harvard Gazette · Jul 21
Study Finds 1 in 3 U.S. Adults Miss 2026 LDL Goals, Rising to 4 in 5 Heart Patients
3 articles · Updated · Harvard Gazette · Jul 21
Summary
Nearly 1 in 3 U.S. adults without heart disease and almost 4 in 5 with prior cardiovascular events have LDL cholesterol above the new 2026 guideline targets, a JAMA study found.
About 76% of above-target adults in the primary-prevention group were on no cholesterol-lowering medication, while 62% of above-target heart-disease patients were already treated but still not at goal.
The analysis used NHANES 2021-2023 data from about 2,300 adults aged 30 to 79, representing roughly 178 million Americans, to set a baseline before the new guidelines are adopted.
The 2026 ACC/AHA guidelines lowered LDL goals and tied them more closely to cardiovascular risk, with treatment considered at 160 mg/dL for low-risk adults and targets below 55 mg/dL for very high-risk patients.
Researchers said the findings point to two distinct gaps—starting therapy for many untreated adults and intensifying therapy for higher-risk patients—amid persistent barriers including access, awareness and health-system constraints.
We have the tools to prevent heart disease, so why are 80% of high-risk patients still missing their cholesterol targets?
New guidelines target a silent genetic heart risk. Why might your cholesterol numbers not tell the whole story?
With stricter cholesterol goals, are we medicalizing millions of people unnecessarily or are we saving their lives?
Millions Missing the Mark: The 2026 Cholesterol Guidelines and America’s Struggle to Meet New LDL Targets
Overview
The 2026 ACC/AHA/Multisociety Dyslipidemia Guideline marks a major shift in cholesterol management, introducing more aggressive LDL-C targets for high-risk individuals. This change responds to long-standing challenges like limited access to new medications, gaps in patient awareness, and systemic healthcare barriers. By setting stricter goals and encouraging earlier intervention, the guidelines aim to drive progress and narrow the treatment gap over time. Supported by recent clinical trial findings, these updates reflect an evolving approach that emphasizes early, effective treatment to reduce cardiovascular risk and improve long-term health outcomes.